Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Response to pneumococcal conjugate and polysaccharide vaccination in children with rheumatic disease

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Hyperhidrosis and human leucocyte antigens in the Danish Blood Donor Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Insights into the toll-like receptors in sexually transmitted infections

    Research output: Contribution to journalReviewResearchpeer-review

  1. Changing Patterns in Treatment, Remission Status, and Categories in a Long-Term Nordic Cohort Study of Juvenile Idiopathic Arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Uveitis in Juvenile Idiopathic Arthritis: 18-Year Outcome in the Population-based Nordic Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Indirekte effekter af COVID-19 på dødeligheden blandt mødre g børn i lav- og mellemindkomstlande

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Response to influenza vaccination in immunocompromised children with rheumatic disease: a prospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Children with rheumatic disease and compromised immune system have an increased risk of infection. Streptococcus pneumoniae is a frequent pathogen, and immunization is recommended. In this study, we investigated whether immunocompromised children with rheumatic disease do respond to pneumococcal immunization with 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine. The study was conducted at two tertiary referral hospitals in Denmark from 2015 to 2018. Patients with rheumatic disease and compromised immune system aged 2-19 years were eligible. Patients were vaccinated with 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine. A blood sample was collected before vaccination and after each vaccination. IgG antibodies were quantified for twelve serotypes. Seroprotection for each serotype was defined as IgG ≥0.35 µg/mL. A total of 27 patients were enrolled. After the conjugate vaccine, an increase in antibody titres compared with pre-vaccination was found for all serotypes and 9/12 were significant. After the polysaccharide vaccine, the antibody titres for all serotypes but one was seen to increase but none reached significance. The proportion of patients protected before immunization ranged from 20.8% to 100% for the individual serotypes. Odds ratio for achieving seroprotection after the conjugate vaccine was >1 for 10/12 serotypes but only significant for three serotypes. After the polysaccharide vaccine, the odds ratio was >1 for 9/12 serotypes but none reached significance. In conclusion, children with rheumatic disease and compromised immune system respond to pneumococcal immunization with 13-valent pneumococcal conjugate vaccine and maintain antibody levels upon subsequent immunization with 23-valent pneumococcal polysaccharide vaccine.

Original languageEnglish
Article numbere13118
JournalScandinavian Journal of Immunology
Volume95
Issue number2
Pages (from-to)e13118
ISSN0300-9475
DOIs
Publication statusPublished - Feb 2022

Bibliographical note

© 2021 The Scandinavian Foundation for Immunology.

ID: 72890229